S'abonner

Exhaled SARS-CoV-2 quantified by face-mask sampling in hospitalised patients with COVID-19 - 12/05/21

Doi : 10.1016/j.jinf.2021.03.018 
Caroline M. Williams a, b, c, , 1 , Daniel Pan a, c, 1, Jonathan Decker a, 1, Anika Wisniewska a, Eve Fletcher a, Shirley Sze d, Sara Assadi c, Richard Haigh a, Mohamad Abdulwhhab a, Paul Bird a, b, Christopher W Holmes a, b, Alaa Al-Taie e, Baber Saleem f, Jingzhe Pan f, Natalie J Garton a, Manish Pareek a, c, 2 , Michael R Barer a, b, 2
a Department of Respiratory Sciences, University of Leicester, United Kingdom 
b Department of Clinical Microbiology, University Hospitals of Leicester NHS Trust, United Kingdom 
c Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom 
d Department of Cardiovascular Sciences, University of Leicester, United Kingdom 
e Department of Biomedical Engineering, Al-Nahrain University, Baghdad, Iraq 
f Department of Engineering, University of Leicester, United Kingdom 

Corresponding author at: Department of Respiratory Sciences, University of Leicester, LE1 9HN, United Kingdom.Department of Respiratory SciencesUniversity of LeicesterLE1 9HNUnited Kingdom

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Highlights

We present a novel method to detect SARS-CoV-2 in exhaled breath using sampling strips fixed within facemasks that can be readily removed and analysed using RT-qPCR (face-mask sampling, FMS).
In 66 hospitalised patients 38% were FMS positive within 24 h of a routinely positive SARS-CoV-2 PCR by nasopharyngeal swab.
Higher FMS viral loads were associated with higher ISARIC deterioration and mortality scores, respiratory symptoms at time of sampling and shorter intervals between symptom onset and sampling.

Le texte complet de cet article est disponible en PDF.

Summary

Background

Human to human transmission of SARS-CoV-2 is driven by the respiratory route but little is known about the pattern and quantity of virus output from exhaled breath. We have previously shown that face-mask sampling (FMS) can detect exhaled tubercle bacilli and have adapted its use to quantify exhaled SARS-CoV-2 RNA in patients admitted to hospital with Coronavirus Disease-2019 (COVID-19).

Methods

Between May and December 2020, we took two concomitant FMS and nasopharyngeal samples (NPS) over two days, starting within 24 h of a routine virus positive NPS in patients hospitalised with COVID-19, at University Hospitals of Leicester NHS Trust, UK. Participants were asked to wear a modified duckbilled facemask for 30 min, followed by a nasopharyngeal swab. Demographic, clinical, and radiological data, as well as International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) mortality and deterioration scores were obtained. Exposed masks were processed by removal, dissolution and analysis of sampling matrix strips fixed within the mask by RT-qPCR. Viral genome copy numbers were determined and results classified as Negative; Low: ≤999 copies; Medium: 1000–99,999 copies and High ≥ 100,000 copies per strip for FMS or per 100 µl for NPS.

Results

102 FMS and NPS were collected from 66 routinely positive patients; median age: 61 (IQR 49 - 77), of which FMS was positive in 38% of individuals and concomitant NPS was positive in 50%. Positive FMS viral loads varied over five orders of magnitude (<10–3.3 x 106 genome copies/strip); 21 (32%) patients were asymptomatic at the time of sampling. High FMS viral load was associated with respiratory symptoms at time of sampling and shorter interval between sampling and symptom onset (FMS High: median (IQR) 2 days (2–3) vs FMS Negative: 7 days (7–10), p = 0.002). On multivariable linear regression analysis, higher FMS viral loads were associated with higher ISARIC mortality (Medium FMS vs Negative FMS gave an adjusted coefficient of 15.7, 95% CI 3.7–27.7, p = 0.01) and deterioration scores (High FMS vs Negative FMS gave an adjusted coefficient of 37.6, 95% CI 14.0 to 61.3, p = 0.002), while NPS viral loads showed no significant association.

Conclusion

We demonstrate a simple and effective method for detecting and quantifying exhaled SARS-CoV-2 in hospitalised patients with COVID-19. Higher FMS viral loads were more likely to be associated with developing severe disease compared to NPS viral loads. Similar to NPS, FMS viral load was highest in early disease and in those with active respiratory symptoms, highlighting the potential role of FMS in understanding infectivity.

Le texte complet de cet article est disponible en PDF.

Graphical abstract




Image, graphical abstract

Le texte complet de cet article est disponible en PDF.

Plan


© 2021  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 82 - N° 6

P. 253-259 - juin 2021 Retour au numéro
Article précédent Article précédent
  • Manipulating the infant respiratory microbiomes to improve clinical outcomes: A review of the literature
  • Anastasia A Theodosiou, Robert B Dorey, Jay R Laver, David W Cleary, Robert C Read, Christine E Jones
| Article suivant Article suivant
  • Sensitivity of SARS-CoV-2 RNA polymerase chain reaction using a clinical and radiological reference standard
  • Alexander J Stockdale, Fred Fyles, Catriona Farrell, Joe Lewis, David Barr, Kathryn Haigh, Michael Abouyannis, Beth Hankinson, Diana Penha, Rashika Fernando, Rebecca Wiles, Sheetal Sharma, Nuria Santamaria, Vijay Chindambaram, Cairine Probert, Muhammad Shamsher Ahmed, James Cruise, Imogen Fordham, Rory Hicks, Alice Maxwell, Nick Moody, Tamsin Paterson, Katharine Stott, Meng-San Wu, Michael Beadsworth, Stacy Todd, Elizabeth Joekes

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.